A systematic review of modeling approaches to evaluate treatments for relapsed refractory multiple myeloma: critical review and considerations for future health …
A Freitag, G Sarri, A Ta, L Gurskyte, D Cherepanov… - …, 2024 - Springer
Abstract Background and Objective Multiple myeloma is a rare incurable hematological
cancer in which most patients relapse or become refractory to treatment. This systematic …
cancer in which most patients relapse or become refractory to treatment. This systematic …
A systematic review of cost-effectiveness analyses of novel agents in the treatment of multiple myeloma
MR Seefat, DGJ Cucchi, S Dirven, K Groen… - Cancers, 2021 - mdpi.com
Simple Summary New treatments in multiple myeloma are embraced by patients and
physicians but are also associated with substantial higher costs. To ensure the affordability …
physicians but are also associated with substantial higher costs. To ensure the affordability …
Cost effectiveness of triplet selinexor-bortezomib-dexamethasone (XVd) in previously treated multiple myeloma (MM) based on results from the phase III BOSTON trial
M Dolph, G Tremblay, H Leong - Pharmacoeconomics, 2021 - Springer
Abstract Background and Objective Nearly all patients with multiple myeloma undergo
multiple rounds of therapy. The phase III BOSTON trial of once-weekly selinexor and once …
multiple rounds of therapy. The phase III BOSTON trial of once-weekly selinexor and once …
Systematic literature review of health economic models developed for multiple myeloma to support future analyses
Aims The goal of this study was to review the economic evaluations of health technologies in
multiple myeloma (MM) and provide guidance and recommendations for future health …
multiple myeloma (MM) and provide guidance and recommendations for future health …
Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma: A summary from the …
M Beinfeld, S Lee, B McQueen, N Fluetsch… - Journal of Managed …, 2021 - jmcp.org
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California
Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and …
Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and …
Клинико-экономические исследования фармакотерапии множественной миеломы: данные литературного обзора
ЕА Лучинин, МВ Журавлева… - Южно-Российский …, 2024 - therapeutic-j.ru
Аннотация Среди гематологических заболеваний Множественная миелома (ММ)
является вторым наиболее распространённым злокачественным новообразованием у …
является вторым наиболее распространённым злокачественным новообразованием у …
[PDF][PDF] Treatments for relapsing and/or refractory multiple myeloma. A health technology assessment
AS Desser, IK Ohm, CJ Rose, FT Chaudhry, GE Næss… - 2023 - fhi.brage.unit.no
This Health Technology Assessment (HTA) was commissioned by the Regional Health
Authorities (RHA) forum: The National System for Managed Introduction of New Health …
Authorities (RHA) forum: The National System for Managed Introduction of New Health …
Análisis estadístico del flujo de pacientes del servicio de extracciones en el Hospital Universitario Río Hortega
C Berruezo Fernández - 2021 - uvadoc.uva.es
Hoy en día, el sector sanitario es uno de los más grandes y con mayor potencial del mundo,
en el que innovación es cada vez mayor. En los próximos años se incrementará …
en el que innovación es cada vez mayor. En los próximos años se incrementará …
Aplicación de la simulación de eventos discretos en el sector sanitario. Construcción de un gemelo digital para el proceso de extracciones de laboratorio
C Berruezo Fernández - 2021 - uvadoc.uva.es
Hoy en día el sector sanitario es uno de los más grandes y con mayor crecimiento del
mundo. La innovación es constante y las políticas de gestión de pacientes están en el punto …
mundo. La innovación es constante y las políticas de gestión de pacientes están en el punto …